Our Network of Board-Certified Providers
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
Three placebo-controlled randomized trials and one cardiovascular outcomes trial published in the New England Journal of Medicine form the evidence base for FDA-approved GLP-1 medications. These trials enrolled thousands of participants across 56–72 week treatment periods and represent the most robust dataset in obesity pharmacotherapy.
Medically reviewed by
Dr. Sarah Mitchell, MD, ABOM
Board-Certified in Obesity Medicine • Last reviewed: June 5, 2026
In the STEP 1 trial (NEJM, 2021), once-weekly semaglutide 2.4 mg produced a mean 15.3% body weight reduction over 68 weeks among 1,306 adults with obesity or overweight — compared to 2.6% with placebo. Ozempic targets type 2 diabetes; Wegovy targets chronic weight management.
The SURMOUNT-1 trial (NEJM, 2022) demonstrated tirzepatide 15 mg reduced mean body weight by 22.5% over 72 weeks in 2,539 adults with obesity. As a dual GIP/GLP-1 agonist, tirzepatide (Mounjaro for diabetes, Zepbound for weight loss) achieves superior results versus single-receptor GLP-1 agents.
The SCALE Obesity trial (NEJM, 2015) confirmed liraglutide 3.0 mg (Saxenda) reduces mean body weight by 8.4% over 56 weeks in adults with obesity; 63.2% of participants lost ≥5% of body weight vs. 27.1% with placebo. Daily injection with the most extensive long-term safety dataset of any GLP-1 medication.
Physician-prescribed GLP-1 medications are supported by phase III randomized controlled trial data published in the New England Journal of Medicine — the standard of evidence in obesity pharmacotherapy:
GLP-1 receptor agonists are not controlled substances under DEA scheduling. They may be prescribed via telehealth consultation under Oklahoma law after a valid clinical evaluation by a OK-licensed physician.
Oklahoma authorizes licensed physicians to prescribe FDA-approved medications via telehealth after establishing a valid patient-physician relationship through a synchronous or asynchronous online consultation. OK-licensed physicians in our network comply with all applicable Oklahoma Medical Practice Act provisions governing telehealth consultations, electronic prescribing, and controlled-substance rules.
GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) are not controlled substances under DEA scheduling. They may be prescribed through a standard telehealth consultation under Oklahoma law without requiring an in-person visit. All consultations use HIPAA-compliant encrypted platforms. Prescriptions are transmitted electronically to licensed US pharmacies, which then arrange home delivery to Harmon addresses.
Residents of Harmon, Oklahoma can complete the entire consultation process online. Board-certified OK-licensed physicians review your clinical profile and, when medically appropriate, issue a prescription for an FDA-approved GLP-1 medication.
Complete a structured clinical intake covering your BMI, weight history, metabolic markers, current medications, and relevant comorbidities (type 2 diabetes, hypertension, cardiovascular disease). This intake provides the prescribing physician with the clinical context required under Oklahoma telehealth guidelines to conduct a valid evaluation.
A board-certified, OK-licensed physician reviews your intake and conducts a HIPAA-compliant telehealth consultation. The physician evaluates your eligibility based on FDA-approved indications (BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity) and selects the most clinically appropriate GLP-1 medication for your individual profile.
If a prescription is issued, it is transmitted electronically to a licensed US pharmacy. Medication is shipped in temperature-controlled packaging to your Harmon address, typically within 3–5 business days. Cold-chain requirements for injectable GLP-1 medications are maintained throughout the shipping process per USP storage standards.
Your prescribing physician schedules follow-up consultations to monitor weight response, assess tolerability, and adjust dosing per the published escalation schedules for each medication. Typical escalation for semaglutide spans 16–20 weeks; tirzepatide escalation spans 20 weeks to maximum dose. Ongoing monitoring is documented in your HIPAA-compliant patient record.
In-person weight management clinics in Harmon often have wait times of 4–12 weeks for an initial appointment. Telehealth consultations with OK-licensed physicians provide the same standard of clinical care — including a full medical history review, FDA-approved medication selection, and documented follow-up — from any location in Harmon.
All GLP-1 prescriptions issued through this platform come from licensed OK physicians following the same FDA-approved indications and prescribing guidelines that apply in an in-person clinic setting. Medications are sourced exclusively from licensed US pharmacies with verified supply chains.
Residents of communities near Harmon can also access GLP-1 telehealth care from board-certified OK-licensed physicians through this platform.
Board-certified physicians serve residents across all major cities in Oklahoma through HIPAA-compliant telehealth consultations.
FDA-approved GLP-1 receptor agonist prescriptions are available through our telehealth network in cities across the United States.
Local weight loss and GLP-1 providers serving the Harmon, OK area, based on Google Business listings.
Oakland, ME
(207) 716-1555
5/5 ★ (129 reviews)
Visit website →Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
Yes. Oklahoma authorizes licensed physicians to prescribe medications — including GLP-1 receptor agonists — via telehealth after a clinically appropriate online evaluation. GLP-1 medications are not controlled substances, so no in-person visit is required under Oklahoma telehealth statutes.
FDA-approved options available through telehealth in Oklahoma include semaglutide (Ozempic for type 2 diabetes; Wegovy for chronic weight management), tirzepatide (Mounjaro for type 2 diabetes; Zepbound for obesity), and liraglutide (Saxenda for weight management). Your OK-licensed physician selects the most appropriate medication based on your BMI, comorbidities, and medical history.
Wegovy (semaglutide) and Zepbound (tirzepatide) are FDA-approved for adults with a BMI ≥30, or BMI ≥27 with at least one weight-related condition (hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea). Saxenda (liraglutide) is approved under the same BMI thresholds. Your physician conducts a clinical evaluation to confirm you meet the approved criteria.
The SURMOUNT-1 trial showed tirzepatide achieves greater mean weight loss (22.5%%) than semaglutide in the STEP 1 trial (15.3%%). However, the prescribing decision depends on your individual clinical profile: existing type 2 diabetes diagnosis, cardiovascular risk factors, insurance coverage, and tolerability history. Your physician will document their clinical rationale for the selected medication.
Your OK-licensed prescribing physician schedules follow-up consultations to review your weight response, adjust dosing per published escalation schedules, and assess tolerability. Side effects such as nausea, vomiting, or gastrointestinal symptoms are common during dose escalation and are documented and managed as part of your ongoing care.
Black Box Warning: In rodent studies, semaglutide and tirzepatide caused thyroid C-cell tumors. It is unknown whether GLP-1 receptor agonists cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. These medications are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Common side effects may include nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and injection site reactions. These typically diminish as dosage is gradually escalated.
Serious side effects may include pancreatitis, gallbladder problems, kidney injury, hypoglycemia (with insulin), and allergic reactions. Consult your healthcare provider immediately if you experience severe symptoms.
Contraindications: History of medullary thyroid carcinoma, MEN 2, pancreatitis, pregnancy or breastfeeding, severe gastrointestinal disease. This is not a complete list — always discuss your full medical history with your physician.
Clinical References:
